Home › Compare › AQSZF vs QYLD

AQSZF vs QYLD: Dividend Comparison 2026

AQSZF yields 51282.05% · QYLD yields 11.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AQSZF wins by $6.164318307325471e+23M in total portfolio value
10 years
AQSZF
AQSZF
● Live price
51282.05%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.164318307325471e+23M
Annual income
$614,076,267,853,163,140,000,000,000,000.00
Full AQSZF calculator →
QYLD
Global X Nasdaq 100 Covered Call ETF
● Live price
11.92%
Share price
$17.15
Annual div
$2.04
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.4K
Annual income
$5,659.31
Full QYLD calculator →

Portfolio growth — AQSZF vs QYLD

📍 AQSZF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAQSZFQYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AQSZF + QYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
AQSZF pays
QYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AQSZF
Annual income on $10K today (after 15% tax)
$4,358,974.36/yr
After 10yr DRIP, annual income (after tax)
$521,964,827,675,188,650,000,000,000,000.00/yr
QYLD
Annual income on $10K today (after 15% tax)
$1,013.51/yr
After 10yr DRIP, annual income (after tax)
$4,810.41/yr
At 15% tax rate, AQSZF beats the other by $521,964,827,675,188,650,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AQSZF + QYLD for your $10,000?

AQSZF: 50%QYLD: 50%
100% QYLD50/50100% AQSZF
Portfolio after 10yr
$3.0821591536627355e+23M
Annual income
$307,038,133,926,581,570,000,000,000,000.00/yr
Blended yield
99.62%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AQSZF buys
0
QYLD buys
0
No recent congressional trades found for AQSZF or QYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAQSZFQYLD
Forward yield51282.05% ✓11.92%
Annual dividend / share$2.00$2.04 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$6.164318307325471e+23M$25.4K ✓
Annual income after 10y$614,076,267,853,163,140,000,000,000,000.00 ✓$5,659.31
Total dividends collected$6.16277212408334e+23M$27.1K ✓
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: AQSZF vs QYLD ($10,000, DRIP)

YearAQSZF PortfolioAQSZF Income/yrQYLD PortfolioQYLD Income/yrGap
1← crossover$5,138,905$5,128,205.13$10,352$1,192.36+$5.13M → AQSZF
2$2,468,429,435$2,462,930,806.71$10,830$1,347.57+$2468.42M → AQSZF
3$1,108,293,458,836$1,105,652,239,339.88$11,460$1,539.07+$1108293.45M → AQSZF
4$465,133,359,857,093$463,947,485,856,138.75$12,275$1,777.84+$465133359.84M → AQSZF
5$182,471,032,796,869,920$181,973,340,101,822,850.00$13,323$2,078.95+$182471032796.86M → AQSZF
6$66,912,846,333,441,070,000$66,717,602,328,348,430,000.00$14,667$2,463.34+$66912846333441.05M → AQSZF
7$22,936,650,503,380,730,000,000$22,865,053,757,803,946,000,000.00$16,396$2,960.57+$22936650503380732.00M → AQSZF
8$7,349,564,359,975,759,000,000,000$7,325,022,143,937,141,000,000,000.00$18,631$3,612.97+$7349564359975758848.00M → AQSZF
9$2,201,460,634,938,307,300,000,000,000$2,193,596,601,073,133,400,000,000,000.00$21,548$4,482.15+$2.2014606349383072e+21M → AQSZF
10$616,431,830,732,547,100,000,000,000,000$614,076,267,853,163,140,000,000,000,000.00$25,398$5,659.31+$6.164318307325471e+23M → AQSZF

AQSZF vs QYLD: Complete Analysis 2026

AQSZF — Stock

Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Evolve dry eye products for various symptoms involved with dry eye disease and blepharitis, including discomfort, stinging, burning, and dryness; and preservative free ophthalmic product. Its development stage product includes Topiramate XR and Oxcarbazepine XR extended-release oral tablets for the treatment of epilepsy; AQS1303, a transdermal pyridoxine/doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304, a cannabinoid based therapeutics for neurological disorders. The company has collaboration agreements with Sandoz Canada, Inc. for the promotion of Vistitan; Supernus Pharmaceuticals, Inc. for marketing of extended-release anti-epileptic drugs; and Medicom Healthcare Ltd. to focus on preservative free therapies in ophthalmology. Aequus Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Full AQSZF Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →
📬

Get this AQSZF vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AQSZF vs SCHDAQSZF vs JEPIAQSZF vs OAQSZF vs KOAQSZF vs MAINAQSZF vs XYLDAQSZF vs JEPQAQSZF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.